FSD Pharma (FSD Pharma) Common Stock : $137.78 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is FSD Pharma Common Stock?

FSD Pharma's quarterly common stock increased from Jun. 2023 ($137.46 Mil) to Sep. 2023 ($137.76 Mil) and increased from Sep. 2023 ($137.76 Mil) to Dec. 2023 ($137.78 Mil).

FSD Pharma's annual common stock declined from Dec. 2021 ($152.33 Mil) to Dec. 2022 ($143.41 Mil) and declined from Dec. 2022 ($143.41 Mil) to Dec. 2023 ($137.78 Mil).

FSD Pharma Common Stock Historical Data

The historical data trend for FSD Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FSD Pharma Common Stock Chart

FSD Pharma Annual Data

Trend

Aug15

Aug16

Aug17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

73.74

103.21

152.33

143.41

137.78

FSD Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															143.41	137.44	137.46	137.76	137.78

FSD Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

FSD Pharma (FSD Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FSD Pharma Inc (NAS:HUGE) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

0K9:Germany HUGE:Canada

Address

199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9

Website

https://www.fsdpharma.com

FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The Company operates in two segments: Biotechnology and Strategic Investments.